John Reilly is CEO of Damona Pharmaceuticals. He brings extensive experience in developing innovative medicines and company-building, with deep knowledge and expertise in corporate strategy, business development, and leading teams in preclinical R&D and clinical development.

Prior to joining Damona, Mr. Reilly served as President & CEO of Apic Bio, a gene therapy company focused on rare neurodegenerative and liver diseases. He has also served as Vice President of Business Development at Tetragenetics (acquired by Abcellera) and was the founder and CEO of Gendyne Therapeutics.

Mr. Reilly is active in the Massachusetts biotechnology ecosystem, having served as a mentor for the MassBioDrive program, and he currently sits on the committee for Cornell Innovation & Venture Advisors (CIVA). He holds a BA from Hamilton College and MS and MBA degrees from Cornell University.

• 

  Chief Executive Officer (CEO) in DAMONA Pharmaceuticals

  Restoring cognitive functions across brain disorders